These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32518552)

  • 1. Associated Myocarditis: A Predictive Factor for Response?
    Shalata W; Peled N; Gabizon I; Abu Saleh O; Kian W; Yakobson A
    Case Rep Oncol; 2020; 13(2):550-557. PubMed ID: 32518552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data.
    Fan Q; Hu Y; Yang C; Zhao B
    Int Immunopharmacol; 2019 Nov; 76():105866. PubMed ID: 31491729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan.
    Wu CE; Yang CK; Peng MT; Huang PW; Lin YF; Cheng CY; Chang YY; Chen HW; Hsieh JJ; Chang JW
    Front Oncol; 2020; 10():905. PubMed ID: 32582554
    [No Abstract]   [Full Text] [Related]  

  • 6. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
    Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
    Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
    Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
    J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
    Läubli H; Balmelli C; Bossard M; Pfister O; Glatz K; Zippelius A
    J Immunother Cancer; 2015; 3():11. PubMed ID: 25901283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
    Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
    J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
    Atallah-Yunes SA; Kadado AJ; Kaufman GP; Hernandez-Montfort J
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1527-1557. PubMed ID: 31028541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy.
    Yoshida S; Fujimura T; Kambayashi Y; Amagai R; Hashimoto A; Aiba S
    Case Rep Oncol; 2019; 12(3):829-833. PubMed ID: 31762756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy.
    Kambayashi Y; Fujimura T; Kuroda H; Otsuka A; Irie H; Aiba S
    Case Rep Oncol; 2020; 13(1):474-477. PubMed ID: 32508619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
    Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
    Front Oncol; 2020; 10():91. PubMed ID: 32117745
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.